Systemic administration of the VMAT2 inhibitor reserpine induces PD-like motor symptoms [36, 37] and nonmotor symptoms [38] in mice, as well as oxidative stress in the striatum [39, 40] and prefrontal cortex [39] of rat brain. This evidence concerns the gene SLC18A2 and Parkinson disease.